期刊文献+

疏肝解郁胶囊联合利培酮口服液治疗精神分裂症急性期疗效及对认知功能和血浆NPY、LP和ChE水平的影响观察 被引量:7

Efficacy of Shugan Jieyu Capsule Combined with Risperidone Oral Solution on Acute Phase of Schizophrenia and its Effects on Cognitive Function and Plasma Levels of NPY,LP and ChE
下载PDF
导出
摘要 目的探究疏肝解郁胶囊联合利培酮口服液治疗精神分裂症急性期的疗效及对患者认知功能、血浆神经肽Y(NPY)、瘦素(LP)和胆碱酯酶(ChE)水平的影响。方法随机数字表格法将本院2017年1月-2018年1月收治的120例急性期精神分裂患者分为观察组(n=60)与对照组(n=60)。分别予以利培酮口服液联合疏肝解郁胶囊、利培酮口服液单药治疗,疗程均为6周。治疗前后采用阳性和阴性症状量表(PANSS)评分,蒙特利尔认知评估量表(Mo-CA)评价疗效及认知功能,观察血浆NPY、LP和ChE水平变化。结果观察组总有效率95.00%,显著高于对照组的80.00%(P<0.05);两组治疗后Mo-CA评分均升高,且观察组显著高于对照组(P<0.05);两组治疗后NPY、LP水平均显著升高,ChE水平显著下降(P<0.05);观察组治疗后ChE水平显著低于对照组(P<0.05),观察组不良反应发生率显著低于对照组(P<0.05)。结论疏肝解郁胶囊、利培酮口服液联合用药能显著提高精神分裂者认知功能,且不加重利培酮引起的NPY、LP水平变化、体质量改变的副作用,安全有效。 Objective To explore the efficacy of Shugan Jieyu capsule combined with risperidone oral solution in the treatment of acute phase of schizophrenia and its effects on cognitive function and plasma levels of neuropeptide Y(NPY),leptin(LP)and cholinesterase(ChE).Methods 120 cases of patients with acute phase of schizophrenia admitted to our hospital from January 2017 to January 2018 were divided into observation group(n=60)and control group(n=60)according to the random number table method.They were given risperidone oral solution combined with Shugan Jieyu capsule,and risperidone oral solution respectively,and they were treated for 6 weeks.The Positive And Negative Symptom Scale(PANSS)scores and Montreal Cognitive Assessment Scale(Mo-CA)were used to evaluate the efficacy and cognitive function before and after treatment,and the changes of plasma NPY,LP and ChE were observed.Results The total effective rate in observation group was significantly higher than that in control group(95.00%vs 80.00%)(P<0.05).The Mo-CA scores in the two groups were increased after treatment,and the score in observation group was significantly higher than that in control group(P<0.05).After treatment,the levels of NPY and LP were significantly increased while the level of ChE was significantly decreased(P<0.05).The level of ChE in observation group after treatment was significantly lower than that in control group(P<0.05),and the incidence rate of adverse reactions in observation group was significantly lower than that in control group(P<0.05).Conclusion Shugan Jieyu capsule combined with risperidone oral solution can significantly improve the cognitive function of schizophrenic patients,and it does not aggravate the side effects of NPY and LP changes and body mass changes caused by risperidone,and it is safe and effective.
作者 岳凌峰 马敬 YUE Ling-feng;MA Jing(Fourth Department of Psychiatry,The Second Affiliated Hospital of Xinxiang Medical College,Xinxiang 453000,Henan Province,China)
出处 《罕少疾病杂志》 2020年第3期1-3,共3页 Journal of Rare and Uncommon Diseases
关键词 疏肝解郁胶囊 利培酮口服液 精神分裂症急性期 认知功能 Shugan Jieyu Capsule Risperidone Oral Solution.Acute Phase of Schizophrenia Cognitive Function
  • 相关文献

参考文献9

二级参考文献95

  • 1龚兰,卢业成,唐小平,尹炽标,杨湛,雷春亮,贾卫东.血清前白蛋白、胆碱酯酶与肝组织病理损害的相关性研究[J].实用医学杂志,2006,22(15):1732-1734. 被引量:6
  • 2张本,王丰,王学义,陆林,吴寿岭,周永,王静,王克强,马启民,陶钧,刘文勇,张武文.精神分裂症患者伴发代谢综合征的相关因素[J].中国心理卫生杂志,2006,20(10):661-664. 被引量:25
  • 3Rehiman S, Lohani SP, Bhattarai MC. Correlation of serum cholin- esterase level, clinical score at presentation and severity of organo- phosphorous poisoning [J]. JNMA J Nepal Med Assoc, 2008, 47 (170): 47-52.
  • 4Pohanka M. Cholinesterases, a target of pharmacology and toxicolo- gy [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repu, 2011, 155(3): 219-230.
  • 5Mabrouk H, Mechria H, Mechri A, et al. Butyrylcholinesterase activ- ity in schizophrenic patients [J]. Ann Biol Clin (Paris), 2011, 69(6): 647-652.
  • 6Paeitti F,Iannitelli A,Caredda M,et al.Immediate Serum Growth Hormone Decrease as a Potential Index of DopamineRe-lated Response to Electroconvulsive Therapy in Schizophrenic Patients[J].The Journal of ECT,2011,27 (2):119-122.
  • 7Gomez G.Electroconvulsive therapy:present and future.[J]Issues Ment Health Nurs,2011,25(5):473.
  • 8Remington G,SahaA,Chong SA,d al.Augmentation strategies in Clozapine-resistant schizophrenia[J].CNS Drugs,2012,19 (3):843-872.
  • 9Mizuno Y,Bies RR,Remington G,et al. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2012,37 ( 1 ) : 182 - 187.
  • 10Okita K, Kanahara N, Nishimura M,et al. Second-generation antipsychotics and bone turnover in schizophrenia [ J 3. Schizophr Res,2014, 157( 1 - 3) : 137 - 141.

共引文献91

同被引文献105

引证文献7

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部